BioCentury
ARTICLE | Clinical News

Enhanced TCR Therapy: Phase I/II started

July 29, 2013 7:00 AM UTC

Adaptimmune began an open-label, U.S. Phase I/IIa trial to evaluate enhanced TCR therapy in about 6 patients with the human leukocyte antigen serotype A201 (HLA-A201) allele and whose tumors express ...